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   ABSTRACT   
  Objectives      To evaluate the efﬁ  cacy and safety of 
intravenous ofatumumab, a fully human anti-CD20 
monoclonal antibody, in biological-naive, active 
rheumatoid arthritis (RA) patients despite methotrexate 
treatment.  
  Methods      In this double-blind, placebo-controlled, phase 
III study, active RA patients on stable methotrexate 
were randomly assigned to one course of two infusions 
of ofatumumab 700 mg (n=130) or placebo (n=130), 
2 weeks apart. The primary endpoint was the ACR20 
response at week 24. Secondary endpoints included 
ACR50/70, EULAR response, disease activity score based 
on 28 joints using C-reactive protein, adverse events (AE) 
and immunogenicity.   
  Results      At week 24, a greater proportion of patients 
on ofatumumab compared with placebo achieved an 
ACR20 response (50% vs 27%, p<0.001) and a good or 
moderate EULAR response (67% vs 41%, p<0.001). All 
other key secondary efﬁ  cacy endpoints were signiﬁ  cantly 
improved on ofatumumab. Efﬁ  cacy observed by 8 weeks 
was sustained throughout the study. The most common 
AE for ofatumumab versus placebo were rash (21% vs 
<1%) and urticaria (12% vs <1%), mostly occurring 
on the ﬁ  rst infusion day. Overall, ﬁ  rst-dose infusion 
reactions were 68% for ofatumumab and 6% for placebo, 
mostly mild to moderate; second-dose infusion reactions 
markedly declined (<1% and 0%). Serious AE were 
reported in 5% of ofatumumab versus 3% of placebo 
patients. Infection rates were 32% and 26% (serious 
infections <1% and 2%), respectively. One death 
(interstitial lung disease), unrelated to study drug, was 
reported on ofatumumab. No antidrug antibodies were 
detected in ofatumumab patients.   
  Conclusions    Ofatumumab  signiﬁ   cantly  improved 
all clinical outcomes in biological-naive, active RA 
patients with no detectable immunogenicity at week 24. 
No unexpected safety ﬁ  ndings were identiﬁ  ed.   
    Trial Registry     clinical trials.gov registration number 
NCT00611455      
  Ofatumumab (HuMax-CD20) is a human IgG1ĸ 
lytic monoclonal antibody (mAb) that speciﬁ  cally 
binds to the human CD20 antigen inducing potent 
B-cell lysis. The CD20 antigen is expressed only 
by B lymphocytes from the pre-B to the plasma-
cytoid immunoblast stage. Ofatumumab recogn-
ises a unique membrane-proximal epitope on the 
human CD20 molecule, distinct from the epitope 
  recognised by rituximab  1   or by other anti-CD20 
mAb.  2     3   The membrane proximity of this epitope 
probably accounts for the high efﬁ  ciency of B-cell 
killing observed with ofatumumab in both in-vitro 
and in-vivo preclinical studies.  4    –    7   
  In animal models, ofatumumab induced selec-
tive and prolonged B-cell depletion primarily 
mediated by effective complement-dependent 
cytotoxicity and antibody-dependent cell-mediated 
  cytotoxicity.  8     9   Effective complement-dependent 
cytotoxicity may depend on the distance between 
the plasma membrane and the constant parts of the 
sensitising antibody thus enabling the efﬁ  cient and 
rapid engagement of complement activation.  10   
  A phase I/II study of ofatumumab, administered 
as two intravenous infusions of 300, 700 or 1000 mg 
2 weeks apart, in active rheumatoid arthritis (RA) 
patients with an inadequate response to disease-
modifying antirheumatic drugs (DMARD), dem-
onstrated signiﬁ  cant clinical beneﬁ  t and reasonable 
tolerability (improved after the implementation of 
premedication) at all doses investigated when com-
pared with placebo, with the 700 mg dose consid-
ered to be optimal.  11   
  To characterise further the efﬁ  cacy and safety 
proﬁ  le of ofatumumab we conducted a placebo-
controlled phase III trial in patients with active RA 
who had an inadequate response to methotrexate 
therapy and no previous biological treatment expo-
sure. This trial was also designed to investigate the 
effects of ofatumumab on the extent and duration 
of B-cell depletion, biomarkers of clinical response, 
patient-reported outcomes and immunogenicity. 
  METHODS 
    Study design and objectives 
  This was a multicentre, randomised, double-
blind, placebo-controlled, parallel group, phase 
III trial. Patients were enrolled at 36 sites in west-
ern Europe, eastern Europe, South America and 
Asia Paciﬁ  c. The trial is registered at clinicaltrials.
gov number NCT00611455. The ﬁ  rst patient was 
enrolled in January 2008 and the last visit for the 
double-blind phase was in June 2009. The trial 
was conducted in accordance with good clinical 
practice and the Declaration of Helsinki. All par-
ticipating sites received approval from national, 
regional, or investigational centre ethics committee 
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or institutional review boards; each patient provided written 
informed consent. 
  The trial included a 24-week double-blind, placebo-controlled 
period followed by a 120-week open-label extension and a safety 
follow-up. This paper summarises results from the completed, 
placebo-controlled, 24-week double-blind phase only. 
  Eligible patients were randomly assigned (1:1) to receive two 
infusions of either ofatumumab 700 mg or placebo 2 weeks apart 
(one course), added to their stable background methotrexate 
dose. Randomisation was stratiﬁ  ed by rheumatoid factor (RF) 
seropositivity/negativity and region. GlaxoSmithKline prepared 
a computer-generated randomisation schedule and randomisa-
tion was handled centrally through an interactive voice response 
system. An unblinded pharmacist at each site prepared the infu-
sions; ofatumumab and saline (placebo) infusions were indis-
tinguishable. Other study personnel and patients were blinded 
to treatment allocation until the double-blind period was com-
plete. Premedication with antihistamine (certirizine 10 mg or 
equivalent), oral paracetamol 1000 mg and intravenous meth-
ylprednisolone 100 mg was administered 30 min to 2 h before 
each infusion. Patients who did not respond were allowed non-
biological DMARD rescue treatment from week 16; however, 
the use of rescue treatment precluded subsequent entry into 
the open-label period. Breakthrough pain management such as 
analgesics, non-steroidal anti-inﬂ  ammatory drugs and one intra-
articular corticosteroid injection in one joint per 6-month period 
were allowed. The joint receiving an intra-articular injection 
was scored as both swollen and tender in joint count assess-
ments during the following 12-week period. 
  The primary objective was to evaluate the efﬁ  cacy of ofa-
tumumab compared with placebo based on the proportion of 
patients achieving an American College of Rheumatology (ACR) 
20  12   response at week 24. Secondary endpoints included propor-
tions of patients achieving ACR50, ACR70, European League 
Against Rheumatism (EULAR) good or moderate responses,  13   
and mean changes in the disease activity score based on 28 
joints (DAS28) using C-reactive protein (CRP),  14   health assess-
ment questionnaire disability index (HAQ–DI),  15   short-form 
health survey (SF-36v2) and functional assessment of chronic ill-
ness therapy–fatigue version 4 (FACIT–F)  16   at week 24.   
  Patient  population 
  Male and non-pregnant, non-lactating female patients 18 years 
and older, diagnosed with active RA according to ACR 1987 
criteria  17   (RA functional class I, II or III) of 6 months or more 
duration were eligible to participate. Active RA was deﬁ  ned as 
eight or more swollen and eight or more tender joint counts, 
based on 66/68 joint count; either CRP of 1.0 mg/dl or greater or 
erythrocyte sedimentation rate (ESR) of 22 mm/h or greater; and 
DAS28 based on ESR of 3.2 or greater. Patients were required to 
have an inadequate response to methotrexate and to be receiv-
ing methotrexate 7.5–25 mg/week for at least 12 weeks, and at 
a stable dose for at least 4 weeks, before baseline. All patients 
underwent a washout period of at least 4 weeks for all DMARD 
(leﬂ  unomide ≥12 weeks or administration of cholestyramine 
treatment for washout according to the manufacturer’s instruc-
tions) but maintained their concomitant stable methotrexate 
therapy, along with folic acid of 5 mg/week or greater. Oral 
corticosteroids (≤10 mg/day of prednisolone equivalent), non-
steroidal anti-inﬂ  ammatory drugs and one intra-articular injec-
tion of corticosteroid (80 mg methylprednisolone or equivalent) 
in a single joint were permitted. Key exclusion criteria com-
prised previous exposure to any biological and B-cell-depleting 
therapy, other autoimmune diseases, signiﬁ  cant  concurrent, 
uncontrolled medical conditions, neutrophils less than 2×10  9  /l, 
platelets less than 100×10  9  /l, IgG less than 6.94 g/l (below lower 
limits of normal), and positive serology for HIV, hepatitis B or 
C infection. Patients were screened for JC virus using PCR for JC 
viral DNA (Quest Diagnostics, Van Nuys, CA, USA and Heston, 
Middlesex, UK  ) and were excluded if tested positive.   
  Assessments 
  Clinical assessments of disease activity were performed at 
baseline and every 4 weeks to week 24 and included an evalu-
ation of the 68-joint tender joint count and 66-joint swollen 
joint count conducted by an independent assessor (blinded to 
patient-rated outcomes), patient’s pain assessment (visual ana-
logue scale (VAS) 0–100 mm), patient’s and physician’s global 
assessment of disease activity (VAS 0–100 mm), HAQ-DI and 
levels of acute-phase reactants (ESR and CRP). From these data, 
ACR20, ACR50 and ACR70 response rates, mean change in 
DAS28–ESR and DAS28–CRP and EULAR response were deter-
mined. FACIT-F and SF-36v2 were assessed at baseline, week 
16 and week 24. 
  Laboratory investigations included levels of peripheral 
B   lymphocytes measured by ﬂ  uorescence-activated cell sorting 
analysis by the surrogate marker CD19, peripheral T lympho-
cytes measured by CD3, CD4 and CD8 markers, immunoglob-
ulins (IgA, IgM, IgG), RF and immunoglobulins to RF (IgM–RF, 
IgG–RF and IgA–RF), anticyclic citrullinated peptide antibodies 
(anti-CCP), acute phase serum amyloid A, interleukin 6 (IL-6) 
(all performed by Quest Diagnostics) and antibodies to ofatu-
mumab measured using a validated electrochemiluminescence 
meso-scale discovery immunoassay. Positive samples from the 
binding antibody assay were tested in a neutralising antibody 
assay (Clinical Immunology, Biopharm R&D, GlaxoSmithKline, 
King of Prussia, PA, USA).   
  Adverse events (AE) and serious adverse events (SAE) were 
collected throughout the study and coded using the Medical 
Dictionary for Regulatory Activities (MedDRA) version 12. 
Infusion-related events occurring during study drug infusion and 
up to 24 h after completion of the infusion (and likely to repre-
sent clinical signs and symptoms characteristic of ofatumumab 
infusion reactions in patients with RA) were identiﬁ  ed by a 
safety review team before unblinding. Low CD19 cell counts 
were not reported as AE and hospitalisation for completion of 
an infusion was not reported as a SAE. Infections were deter-
mined using the MedDRA system organ class ‘infections and 
infestations’.   
  Sample  size  estimation 
  A sample size of 124 subjects per group was estimated to pro-
vide at least 90% power to detect differences in the proportions 
of patients achieving an ACR20 response at week 24 between 
ofatumumab versus placebo, at a 5% level of signiﬁ  cance. This 
was based on a χ  2   test comparing two binomial proportions.   
  Statistical  analysis 
  For categorical endpoints, the efﬁ   cacy of ofatumumab ver-
sus placebo was analysed using the Cochran Mantel Haenszel 
test, adjusting for baseline stratiﬁ  cation factors, RF status and 
geographical region (ie, eastern Europe, western Europe, South 
America, Asia Paciﬁ  c). For continuous endpoints efﬁ  cacy was 
analysed using analysis of covariance, adjusting for RF status, 
geographical region and baseline value. For categorical end-
points, patients who took disallowed medication or withdrew 
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from the study were imputed as non-responders. For continuous 
endpoints, data were imputed by carrying forward the last value 
recorded before taking disallowed medication or withdrawal 
(last observation carried forward). The intent-to-treat (ITT) pop-
ulation comprised all randomly assigned patients who received 
at least one infusion of the study drug. The safety population 
was identical to the ITT population except that patients were 
analysed according to their actual treatment in case this differed 
from their randomised treatment.     
  RESULTS 
    Disposition of patients and baseline characteristics 
  A total of 344 patients was screened and 265 were enrolled and 
randomly assigned; the reasons for screening failure are shown 
in   ﬁ  gure 1  . Of the 265 randomly assigned patients, 260 (98%) 
were exposed to investigational product and were included in 
the safety and ITT populations (  ﬁ  gure 1  ). One patient was ran-
domly assigned to placebo but received ofatumumab and was 
included in the placebo group for the ITT population (based on 
randomised treatment) and in the ofatumumab group for the 
safety population (based on actual treatment received).   
  Demographics and baseline RA characteristics were balanced 
between the two groups (  table 1  ). Most patients were women 
(82%) and RF positive (84%), with a mean age of 53 years. At 
baseline, mean RA duration was 8.5 years, mean DAS28–CRP 
was 5.7 and mean DAS28–ESR was 6.5 (  table 1  ).     
  Clinical  response 
  At week 24, a greater proportion of patients administered 
ofatumumab 700 mg achieved the primary endpoint of 
ACR20 compared with placebo (50% and 27%, respectively, 
p<0.001). In addition, signiﬁ  cantly greater improvements in 
ACR50 and ACR70 were observed with ofatumumab ver-
sus placebo (ACR50 27% and 11%, p<0.001; ACR70 13% 
and 2%, p=0.001) (  table 2   and   ﬁ  gure 2  ). When examined by 
RF status, the ACR20 response in ofatumumab and placebo 
groups, respectively, was 50% (54/108) versus 26% (29/111) 
for seropositive patients and 48% (10/21) versus 30% (6/20) 
for seronegative patients. When examined by anti-CCP status, 
 Table  1        Demographics and baseline disease characteristics   
 Characteristic    Ofatumumab 700 mg (n=129)   Placebo  (n=131) 
Mean (SD) age, years 51.7 (11.24) 53.6 (11.50)
Female, n (%) 106 (82.2) 108 (82.4)
Caucasian, n (%) 122 (94.6) 129 (98.5)
Mean (SD) disease 
duration, years
7.93 (7.230) 9.07 (8.987)
Median (min, max) 
methotrexate dose, mg/week
15.0 (7.5, 25) 15.0 (7.5, 25)
Previous DMARD, n (%)
  1–2 87 (67.4) 88 (67.2)
  3–4 36 (27.9) 32 (24.4)
  >4 6 (4.7) 11 (8.4)
Patients receiving oral 
corticosteroid, n (%)
75 (58.1) 84 (64.1)
Median (min, max) oral 
corticosteroid dose, mg/day  * 
6.4 (1.6, 15.0) 5.0 (1.6, 12.8)
RF positive, n (%) 108 (83.7) 111 (84.7)
Median (min, max) CRP, mg/l 8.3 (0, 98) 8.3 (0, 68)
Mean (SD) ESR, mm/h 47.1 (25.38) 44.4 (23.69)
Mean (SD) total RF, IU/ml  †  326.5 (593.60) 250.4 (492.71)
Mean (SD) SJC (66 joints) 16.2 (7.41) 15.7 (6.88)
Mean (SD) TJC (68 joints) 28.7 (13.36) 26.6 (12.59)
Mean (SD) DAS28–CRP 5.83 (0.794) 5.63 (0.800)
Mean (SD) DAS28–ESR 6.59 (0.828) 6.41 (0.782)
Mean (SD) HAQ–DI 1.7 (0.67) 1.5 (0.65)
Mean (SD) FACIT–F 25.2 (10.00) 29.5 (9.54)
   *  Prednisolone  equivalent  dose.  
  †  At  screening.  
    CRP, C-reactive protein; DAS28, disease activity score based on 28 joints; DMARD, 
disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; FACIT–F, 
functional assessment of chronic illness therapy–fatigue; HAQ–DI, health assessment 
questionnaire disability index; RF, rheumatoid factor; SJC, swollen joint count; 
TJC, tender joint count.     
 Figure  1     Disposition of patients up to week 24. *Patients could have more than one reason for screening failure. †One patient was randomly 
assigned to placebo but received ofatumumab. This patient is included in the placebo group for the intent-to-treat population, but in the ofatumumab 
group for the safety population.       
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the ACR20 response in ofatumumab and placebo groups, 
respectively, was 50% (56/111) versus 26% (29/113) for sero-
positive patients and 44% (7/16) versus 31% (5/16) for sero-
negative patients.     
  All other secondary efﬁ   cacy endpoints, including EULAR 
response and mean change from baseline in DAS28–CRP and 
DAS28–ESR were signiﬁ  cantly improved in the ofatumumab 
group compared with placebo, except for clinical remission 
(DAS28–CRP <2.6) (  table 2   and supplementary table S1, avail-
able online only). The mean change from baseline in DAS28–CRP 
scores over the 24-week period showed sustained improvement 
compared with placebo from week 8 to week 24 (  ﬁ  gure 3  ). 
Ofatumumab also provided improvements in patient-reported 
outcomes as shown by signiﬁ  cantly greater changes from base-
line in HAQ–DI, FACIT–F and SF36v2 scores compared with 
placebo (  table 2  ).     
  Laboratory  ﬁ  ndings 
  Peripheral B lymphocytes (CD19) were greatly reduced at each 
visit relative to baseline in the ofatumumab group: median 
reductions at weeks 2 (before the second infusion), 4, 12 and 
24 were 95%, 96%, 96% and 94%, respectively. In the placebo 
group, CD19 cells increased by 3% at week 24. In the ofatu-
mumab group one patient (1%) had a CD19 B-cell count equal 
to or greater than the lower limit of normal (0.11 GI/l) or the 
baseline value at week 24. No trend for a change in periph-
eral CD3, CD4 or CD8 T-cell counts was observed in either 
group.  
    Biomarkers and assessment of immunogenicity 
  At week 24, the median change from baseline in absolute bio-
marker levels for ofatumumab and placebo, respectively, were: 
−4.0 versus −0.4 ng/l for IL-6; −53.5 versus −10.9 mg/ml for 
serum amyloid A; −138 versus 0 units for anti-CCP; −6.3 versus 
0.0 units for RF–IgM; −4.8 versus 0.0 units for RF–IgG and −3.0 
versus 0.0 units for RF–IgA. At week 24, the median change 
from baseline in immunoglobulin levels for ofatumumab and 
placebo, respectively, were: −1.30 versus −0.60 g/l for IgG; 
−0.30 versus −0.02 g/l for IgM and −0.23 versus −0.09 g/l for 
IgA. A small number of patients on ofatumumab or placebo had 
immunoglobulins equal to or less than the lower limit of nor-
mal during the study (IgM 6 vs 4; IgG 3 vs 1; IgA, no patients, 
respectively). No patients treated with ofatumumab developed 
detectable anti-ofatumumab antibodies at week 24.   
 Table  2     Summary of disease-activity and quality-of-life clinical endpoints at week 24 for patients receiving ofatumumab or placebo   
    Ofatumumab 700 mg (n=129)   Placebo  (n=131)    OR (95% CI)   p  Value 
ACR20 64/129 (50%) 35/131 (27%) 2.86 (1.67 to 4.91) <0.001
ACR50 35/129 (27%) 14/131 (11%) 3.29 (1.63 to 6.62) <0.001
ACR70 17/129 (13%) 3/131 (2%) 6.63 (1.87 to 23.51) 0.001
EULAR response  *  87/129 (67%) 54/131 (41%) 3.07 (1.82 to 5.18) <0.001
Clinical remission  †  13/129 (10%) 7/131 (5%) 2.09 (0.76 to 5.77) 0.152
HAQ–DI response  ‡  74/129 (57%) 59/131 (45%) 1.65 (1.01 to 2.70) 0.046
    Ofatumumab 700 mg (n=129)   Placebo  (n=131)    Adjusted mean difference (95% CI)   p  Value 
DAS28–CRP  § 
Baseline, mean (SD) 5.83 (0.794) 5.63 (0.800)    
Week 24, mean (SD) 4.12 (1.270) 4.98 (1.437)    
Adjusted mean (SE) change −1.77 (0.151) −0.77 (0.154) −1.00 (−1.29 to −0.72) <0.001
DAS28–ESR  § 
Baseline, mean (SD) 6.59 (0.828) 6.41 (0.782)    
Week 24, mean (SD) 4.84 (1.360) 5.67 (1.439)    
Adjusted mean (SE) change −1.79 (0.157) −0.80 (0.161) −0.99 (−1.29 to −0.69) <0.001
HAQ–DI  § 
Baseline, mean (SD) 1.7 (0.67) 1.5 (0.65)    
Week 24, mean (SD) 1.2 (0.79) 1.3 (0.74)    
Adjusted mean (SE) change −0.53 (0.077) −0.32 (0.078) −0.22 (−0.37 to −0.07) 0.004
FACIT–F  ¶ 
Baseline, mean (SD) 25.2 (10.00) 29.5 (9.54)    
Week 24, mean (SD) 32.0 (11.52) 30.2 (10.86)    
Adjusted mean (SE) change 7.29 (1.353) 3.55 (1.394) 3.75 (1.11 to 6.39) 0.006
SF-36 physical component summary score  *    * 
Baseline, mean (SD) 29.9 (6.73) 31.9 (7.32)    
Week 24, mean (SD) 35.9 (9.28) 34.8 (8.79)    
Adjusted mean (SE) change 6.69 (1.031) 4.21 (1.048) 2.48 (0.51 to 4.45) 0.014
SF-36 mental component summary score  *    * 
Baseline, mean (SD) 38.2 (11.77) 40.1 (11.84)    
Week 24, mean (SD) 42.2 (11.38) 40.2 (11.95)    
Adjusted mean (SE) change 4.60 (1.272) 1.57 (1.308) 3.03 (0.61 to 5.46) 0.014
      ACR20/50/70, 20%/50%/70% improvement as per American College of Rheumatology (ACR) criteria.   
    *    EULAR response of moderate or good, based on DAS28–CRP.   
  †    DAS28–CRP score less than 2.6.   
  ‡    Change from baseline HAQ–DI score of 0.22 or greater.   
  §    Negative change represents an improvement. Patient numbers assessed: placebo (n=130); ofatumumab (n=126).   
  *   * Patient  numbers  assessed:  placebo  (n=117);  ofatumumab  (n=116).  
  ¶    Patient numbers assessed: placebo (n=111); ofatumumab (n=114).   
    Results are reported in accordance with EULAR/ACR collaborative recommendations.  33   
    CRP, C-reactive protein; DAS28, disease activity score based on 28 joints; EULAR, European League Against Rheumatism; ESR, erythrocyte sedimentation rate; FACIT–F, functional 
assessment of chronic illness therapy–fatigue; HAQ–DI, health assessment questionnaire disability index; SF-36, short-form health  survey.   
10_annrheumdis151522.indd   2122 10_annrheumdis151522.indd   2122 10/28/2011   8:01:44 PM 10/28/2011   8:01:44 PMExtended report
Ann Rheum Dis 2011;70:2119–2125. doi:10.1136/ard.2011.151522 2123
  Safety 
  The overall incidence of AE was 89% and 55% in ofatumumab 
and placebo groups, respectively (  table 3  ). Within the ofatu-
mumab group the most commonly reported AE were rash 
(21%) and urticaria (12%); these events mostly occurred on the 
day of ﬁ  rst infusion (19% and 12%, respectively). The propor-
tion of patients experiencing an infusion-related AE on the day 
of ﬁ  rst infusion was 68% for ofatumumab and 6% for placebo; 
infusion-related AE on the day of second infusion markedly 
declined (<1% and 0%, respectively). Most AE were of mild or 
moderate intensity. Severe AE were reported for 8% of patients 
on ofatumumab and 2% on placebo, with 5% and less than 1% 
occurring on the day of ﬁ  rst infusion. AE leading to withdrawal 
were 9% for ofatumumab and less than 1% for placebo. Four 
SAE (bacterial gastroenteritis, pneumonia, myocardial infarc-
tion, ischaemic stroke) were reported for four patients (3%) in 
the placebo group and seven SAE (angioedema, interstitial lung 
disease (fatal), synovitis, pulmonary embolism, diarrhoea and 
pneumonia, pericardial effusion) were reported for six patients 
(5%) in the ofatumumab group. Two of these SAE (angioedema, 
pneumonia), both in the ofatumumab group, were considered 
by the investigator to be related to the investigational product. 
There was one fatal SAE of interstitial lung disease in the ofatu-
mumab group, which was not considered by the investigator to 
be related to the investigational product but to RA worsening.   
  AE within the system organ class of infections and infesta-
tions were reported for 26% and 32% of patients on placebo 
and ofatumumab, respectively. None of the events was of severe 
intensity and none led to discontinuation of the investigational 
product or withdrawal from the study. One SAE of pneumonia 
was reported in each group and one SAE of bacterial gastroen-
teritis was reported on placebo ( table 3 ). No serious opportunistic 
infections and no cases of progressive multifocal leukoencephal-
opathy were reported. Two neoplasms, both prostatic adenoma 
and both in the placebo group, were reported.     
  DISCUSSION 
  The results from the 24-week, placebo-controlled, double-blind 
phase of this trial conﬁ  rm the previously reported efﬁ  cacy of 
one course of intravenous ofatumumab in active RA.  11   In addi-
tion, this study provides further information on the efﬁ  cacy 
of ofatumumab in a well-deﬁ  ned RA patient population with 
long-standing disease not controlled by standard methotrexate 
therapy and not previously treated with other available bio-
logical DMARD therapies. Ofatumumab, at a dose of 700 mg 
administered twice, added to a background stable dose of meth-
otrexate therapy, demonstrated a signiﬁ  cantly greater ACR20 
response at week 24 (primary endpoint) compared with placebo. 
Signiﬁ  cantly greater improvements were observed in key sec-
ondary endpoints such as ACR50, ACR70, change from baseline 
in both DAS28–CRP and DAS28–ESR, EULAR response, physi-
cal function (HAQ–DI) and fatigue (FACIT–F). 
  Efﬁ  cacy data from seronegative RA patients, for either RF or 
anti-CCP, as observed in the study, should be interpreted with 
caution because of the small sample size. Data from a number of 
clinical trials with rituximab in a range of RA populations seem 
 Table  3     Safety of placebo and ofatumumab over 24 weeks (safety 
population)  
 
  Patients with AE, n (%) 
  Ofatumumab 700 mg 
(n=130)   Placebo  (n=130) 
Total patient-years of exposure 57 58
Any AE 116 (89) 71 (55)
Any SAE (fatal or non-fatal)  *  6 (5) 4 (3)
Death 1 (<1) 0
AE leading to discontinuation of IP or 
withdrawal from study
12 (9) 1 (<1)
Most common AE (≥5% in either group)
  Rash 27 (21) 1 (<1)
  Urticaria 16 (12) 1 (<1)
  Urinary tract infection 7 (5) 9 (7)
  Headache 6 (5) 8 (6)
  Nasopharyngitis 10 (8) 3 (2)
  Pruritus 10 (8) 2 (2)
  Throat irritation 10 (8) 1 (<1)
 Hypersensitivity 8  (6) 0
 Dyspnoea 7  (5) 0
Infusion reactions    
  Any AE on day of ﬁ  rst infusion 92 (71) 12 (9)
  Infusion-related  reaction  †  89 (68) 8 (6)
  Any AE on day of second infusion 4 (3) 4 (3)
  Infusion-related  reaction  † 1  (<1) 0
Patients with an infection 42 (32) 34 (26)
  No of infections 60 45
  Infections/100 patient-years (95% CI) 105.26 (81.86 to 
135.49)
77.59 
(58.07 to 103.82)
Patients with a serious infection 1 (<1) 2 (2)
  No of infections 1 2
  Infections/100 patient-years (95% CI) 1.75 (0.42 to 9.77) 3.45 
(1.07 to 12.46)
Cardiac disorders    
  Any 7 (5) 6 (5)
  Serious 1 (<1) 1 (<1)
Vascular disorders    
  Any 12 (9) 8 (6)
 Serious 0 0
Neoplasms (benign or malignant)    
 Any 0 2  (2)
 Serious 0 0
      *    SAE were bacterial gastroenteritis, pneumonia, myocardial infarction, ischaemic 
stroke in the placebo group and angioedema, interstitial lung disease (fatal, unrelated 
to ofatumumab), synovitis, pulmonary embolism, diarrhoea and pneumonia, pericardial 
effusion in the ofatumumab group.   
  †    Infusion-related reactions (events likely to represent clinical signs and symptoms 
characteristic of ofatumumab infusion reactions in patients with RA) were identiﬁ  ed by 
a safety review team before unblinding.   
    AE, adverse event; IP, investigational product; RA, rheumatoid arthritis; SAE, serious 
adverse  event.   
 Figure  2        ACR 20/50/70 responses at week 24 in patients receiving 
ofatumumab 700 mg or placebo. ACR20/50/70, 20%/50%/70% 
improvement as per American College of Rheumatology (ACR) criteria.       
10_annrheumdis151522.indd   2123 10_annrheumdis151522.indd   2123 10/28/2011   8:01:44 PM 10/28/2011   8:01:44 PMExtended report
Ann Rheum Dis 2011;70:2119–2125. doi:10.1136/ard.2011.151522 2124
to suggest that seropositive patients (RF and/or anti-CCP) have 
a higher likelihood of response to B-cell-depleting therapy com-
pared with seronegative patients, in particular for improving 
signs and symptoms;  18    –    22   however, the statistical signiﬁ  cance 
of these ﬁ  ndings remains to be determined. Radiographic end-
points were not assessed in this ofatumumab trial and data are 
not currently available for the persistence of response beyond 
24 weeks. 
  The safety information gathered in this study is consistent 
with that observed in short-term studies of rituximab in active 
RA.  18     23     24   Although a greater proportion of patients receiving 
ofatumumab experienced mild to moderate infusion-related 
reactions on the day of ﬁ  rst infusion, despite steroid premedi-
cation, less than 1% of ofatumumab patients experienced an 
infusion-related reaction on the day of second infusion. This 
ﬁ  nding may be explained by the sudden cytokine release that 
follows the pronounced B-cell lysis occurring after CD20 liga-
tion, as previously reported in non-Hodgkin’s lymphoma 
patients treated with rituximab.  25   The rate of serious infections 
in patients treated with ofatumumab was low and comparable 
to placebo. Although progressive multifocal leukoencephalop-
athy has been reported with rituximab,  26   no such cases were 
identiﬁ  ed with ofatumumab in the current small study of lim-
ited duration, which excluded patients who screened positive 
for JC virus DNA at baseline (one patient excluded). Similarly, 
serious opportunistic infections were reported in ocrelizumab 
trials, but were not observed in this study.  27     28   
  Ofatumumab is a fully human mAb, thereby offering a low 
immunogenicity potential. Although all patients in the study 
were on methotrexate, which may suppress the development of 
antidrug antibodies,  29   and patients only received one course of 
treatment over 24 weeks, no anti-ofatumumab antibodies were 
detectable in any of the treated patients. In contrast, 7.9% and 
5.4% of RA patients who received the chimeric mAb rituximab 
500 mg administered twice and 1000 mg administered twice, 
respectively, in a study of a similar patient population, developed 
human antichimeric antibodies at 24 weeks.  19   Overall, 11% of 
patients with RA have tested positive for auto-antibodies at any 
time after receiving rituximab.  26   There was no reported correla-
tion between the development of these human antichimeric anti-
bodies and safety or efﬁ  cacy; nevertheless, the possibility of loss 
or reduction of efﬁ  cacy, local reactions, serum sickness/immune 
complex-mediated disease and major allergic reactions (eg, urti-
caria, bronchospasm, bronchoconstrictions) is well recognised.  30   
In addition to its efﬁ  cacy in RA demonstrated in this trial, ofatu-
mumab is approved for the treatment of refractory chronic lym-
phocytic leukaemia.  31   The mechanism of B-cell tumour lysis is 
probably through the activation of both complement-dependent 
cytotoxicity and antibody-dependent cell-mediated cytotoxicity. 
Compared with rituximab, ofatumumab demonstrates increased 
binding of C1q and more potent complement-dependent cyto-
toxicity, even in chronic lymphocytic leukaemia cells with low 
CD20 expression levels.  32   It is unknown at this time, however, 
whether these mechanistic differences can translate to improved 
safety, tolerability, efﬁ  cacy, or potency over rituximab. 
  In summary, ofatumumab is a fully human mAb binding an 
epitope of CD20 distinct to that recognised by rituximab. A sin-
gle course of two infusions of 700 mg was efﬁ  cacious and safe 
in biological-naive, active RA patients on background metho-
trexate up to 24 weeks after treatment. As expected for a fully 
human mAb, ofatumumab did not induce immunogenicity. 
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